Active endothelial proteins (glucose-related protein—GRP78) or monoclonal antibodies against the vascular endothelial growth factor (bevacizumab) are considered to be factors potentially preventing BBB disruption, a relevant element in NMO background [26]. This evidence concerns the gene HSPA5 and neuromyelitis optica.